Tevogen Bio Holdings Inc., trading on Nasdaq under the ticker symbol TVGN, has announced plans to expand its specialty care pipeline to include patients aged 65 and older, building on a previous revenue forecast of nearly $1 billion in its launch year. The cumulative five-year revenue estimate for Tevogen's specialty pharmaceuticals is projected to range between $18 billion and $22 billion. This expansion is set to enhance the market potential of the company's offerings. An updated forecast and the risk-adjusted net present value (rNPV) will be released to reflect the inclusion of the 65+ patient demographic. In response to the detection of the more contagious COVID variant NB.1.8.1 in the U.S., initially identified in China, Tevogen Bio is prioritizing the expansion of clinical manufacturing capacity to meet significant unmet medical needs.